SCHEMBL8093727

SCHEMBL8093727

CCc1cccc(C)c1C(=O)Br

nearest known ligand 0.45

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
GABRA1 P14867 2/20 0.45
GABRB2 P47870 2/20 0.45
PTGS2 P35354 1/20 0.41
HTT P42858 3/20 0.40
SMN1; SMN2 Q16637 3/20 0.40
MEN1 O00255 2/20 0.40
KMT2A Q03164 2/20 0.40
ITGB1 P05556 1/20 0.40
ITGA4 P13612 1/20 0.40
NLRP3 Q96P20 1/20 0.40
ALDH1A1 P00352 3/20 0.39
TAS1R3 Q7RTX0 1/20 0.39
TAS1R1 Q7RTX1 1/20 0.39
TAS1R2 Q8TE23 1/20 0.39
GPR52 Q9Y2T5 1/20 0.39
HSD17B10 Q99714 1/20 0.39
TP53 P04637 1/20 0.39
CYP3A4 P08684 1/20 0.39
TDP1 Q9NUW8 1/20 0.39
ALOX12 P18054 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL8096271 0.87 ITGB1 (0.43) GABRA1GABRB2ITGB1ITGA4ALDH1A1
SCHEMBL2325202 0.86 GPR52 (0.38) GABRA1GABRB2PTGS2SMN1; SMN2MEN1
SCHEMBL8085908 0.84 BID (0.49) ALDH1A1HSD17B10
SCHEMBL8096193 0.83 BID (0.55) HSD17B10
SCHEMBL6113407 0.83 L3MBTL1 (0.44) HTTSMN1; SMN2MEN1KMT2AALDH1A1
SCHEMBL501450 0.82 GABRA1 (0.46) GABRA1GABRB2PTGS2HTTSMN1; SMN2
SCHEMBL424866 0.82 L3MBTL1 (0.50) GABRA1GABRB2PTGS2ITGB1ITGA4
SCHEMBL13105884 0.82 GABRA1 (0.46) GABRA1GABRB2PTGS2HTTSMN1; SMN2
SCHEMBL8096206 0.81 BID (0.57) HSD17B10
SCHEMBL8100395 0.81 BID (0.57) HSD17B10

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20080051583-A1 NOVEL INTERMEDIATE COMPOUNDS USEFUL IN THE PRODUCTION OF DIARYLCYCLOALKYL DERIVATIVES SANOFI-AVENTIS DEUTSCHLAND GMBH (DE) 2008-02-28 US disclosed
EP-0708077-B1 Diamino compounds and methods for preparing them CHISSO CORP (JP) 2000-12-27 EP disclosed
US-5663440-A Diamino compounds and methods for preparing them CHISSO CORPORATION (JP) 1997-09-02 US disclosed
EP-0708077-A1 Diamino compounds and methods for preparing them CHISSO CORPORATION (JP) 1996-04-24 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080051583-A1 NOVEL INTERMEDIATE COMPOUNDS USEFUL IN THE PRODUCTION OF DIARYLCYCLOALKYL DERIVATIVES PPARG, PPARD, PPARA GABRA1 732/4885GABRB2 566/4885PTGS2 523/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.